Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1003 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2019-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will be carried out to provide supportive clinical data on the feasibility, efficacy, safety, and PK of LPV based therapies in routine treatment setting and will be based on the existing LPV/r pellets which already represent a clear advantage in comparison with the liquid formulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa

NCT02028676

Human Immunodeficiency Virus

COMPLETED PHASE4

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

NCT06133686

HIV

NOT_YET_RECRUITING PHASE3

The Pediatric HIV Nutrition Study in Uganda

NCT02421302

Child Nutrition Disorders

UNKNOWN NA

Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment

NCT01417988

HIV Infection Tuberculosis

TERMINATED PHASE4

Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV

NCT01529125

Kwashiorkor Marasmus Severe Acute Malnutrition +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to evaluate the effectiveness of LPV/r pellets in addition to AZT/3TC (or ABC/3TC) paediatric fixed dose combination (FDCs) tablet under routine treatment conditions in HIV infected infants and young children who cannot swallow tablets.

As secondary objectives:

* Document the safety of LPV/r pellets and AZT/3TC or ABC/3TC
* Assess the population pharmacokinetics of LPV/r and NRTIs when administered as LPV/r pellets plus AZT/3TC or ABC/3TC
* Measure adherence to the new formulation
* Evaluate children acceptability of the LPV/r pellets and associated dual NRTIs as well as ease of use by the care giver.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LPV/RTV pellets and AZT/3TC or ABC/3TC

Only 1 arm. No comparator

Group Type EXPERIMENTAL

LPV/RTV pellets and AZT/3TC or ABC/3TC

Intervention Type DRUG

Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:

* Between 3 and 5.9kg: 2 capsules twice a day
* Between 6 and 9.9kg: 3 capsules twice a day
* Between 10 and 13.9kg: 4 capsules twice a day
* Between 14 and 19.9kg: 5 capsules twice a day
* Between 20 and 24.9kg: 6 capsules twice a day

Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:

* Between 3 and 5.9kg: 1 tablet twice a day
* Between 6 and 9.9kg: 1.5 tablets twice a day
* Between 10 and 13.9kg: 2 tablets twice a day
* Between 14 and 19.9kg: 2.5 tablets twice a day
* Between 20 and 24.9kg: 3 tablets twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LPV/RTV pellets and AZT/3TC or ABC/3TC

Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:

* Between 3 and 5.9kg: 2 capsules twice a day
* Between 6 and 9.9kg: 3 capsules twice a day
* Between 10 and 13.9kg: 4 capsules twice a day
* Between 14 and 19.9kg: 5 capsules twice a day
* Between 20 and 24.9kg: 6 capsules twice a day

Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:

* Between 3 and 5.9kg: 1 tablet twice a day
* Between 6 and 9.9kg: 1.5 tablets twice a day
* Between 10 and 13.9kg: 2 tablets twice a day
* Between 14 and 19.9kg: 2.5 tablets twice a day
* Between 20 and 24.9kg: 3 tablets twice a day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Past or current documentation of a confirmed diagnosis of HIV infection defined as two positive assays from two different samples taken at a different date as preferred option.

* At any age: HIV-1 DNA PCR positivity
* At any time \>4 weeks of age: HIV-1 p24 antigen detection or HIV-1 RNA viral load \> 5,000 copies/mL plasma
* At any age \>18 months: HIV-1 antibody reactive on two different manufacturers' licensed rapid tests based on a different antigen preparation and/or different test principal, or repeatedly reactive on a licensed enzyme immune assay (EIA)and confirmed on a second sample by any one of the following assays: rapid test (a third manufacturer), licensed EIA, Western blot, chemi-luminescence assay, or plasma RNA with a viral load \> 5,000 copies/mL

One single positive PCR assay result will be acceptable for inclusion of a child less than 18 months in the study Although the 2nd PCR assay would not be performed at the time of treatment initiation/treatment switch,

* In case the test is RNA PCR viral load), the sample should be taken before treatment initiation and analyzed as soon as possible thereafter,
* In case the child is already on treatment, the test should be DNA PCR based, the blood sample can be taken while on treatment and the results be made available as soon as possible.
* ARV treatment eligible children with LPV-based treatment indication\* as defined by country-specific guidelines or the WHO pediatric treatment guidelines confirmed by investigator:

1. ARV naïve, or
2. Already on first line liquid lopinavir based treatment, or
3. Failing first line NNRTI based therapy
* Weight ≥3 and \<25 kg at the time of enrolment.
* Inability to swallow tablets\*
* Parent or legal guardian able and willing to provide written informed consent. \*Age is not an inclusion criterion. Children older than 5 years who need a LPV/r based treatment and cannot swallow tablets are eligible. Analysis will be stratified according to study entry point (naïve, first line, failure)

Exclusion Criteria

* Planned or concurrent use of NNRTIs, integrase inhibitors, entry inhibitors, or PIs other than LPV/r.
* PIs treatment failure with the presence or strong suspicion of a PI resistance mutation.
* Clinical condition requiring the use of a prohibited medication in association with LPV/r
* Any clinically significant disease or finding during screening that, in the investigator's opinion, would compromise participation in this study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No